Affiliations 

  • 1 Dr Sargunan Sockalingam, Department of Medicine, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia. Email: sargunan@um.edu.my
  • 2 Sunway Medical Centre, Visiting Consultant, University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 3 Chemical Pathology Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
Int J Rheum Dis, 2009 Sep;12(3):211-5.
PMID: 20374348 DOI: 10.1111/j.1756-185X.2009.01412.x

Abstract

AIM: The objectives of this study are to provide data regarding the prevalence of anti-cyclic citrullinated peptide (CCP) antibodies in Malaysian rheumatoid arthritis (RA) patients and to correlate the levels of anti-CCP antibody with the Disease Activity Score (DAS).
METHOD: We studied the prevalence of anti-CCP antibodies in 51 RA patients attending our clinic and 29 controls. We also looked for correlation between anti-CCP antibody levels with the DAS and parameters such as duration of disease, rheumatoid factor (RF) and disease-modifying anti rheumatic drug (DMARD) usage.
RESULTS: None of the controls demonstrated anti-CCP antibodies. Forty-one out of 51 patients (80.4%) were positive for anti-CCP antibodies. Sensitivity and specificity were 80.4% and 100% respectively in this study. Anti-CCP levels correlated significantly with rheumatoid factor, but no correlation was observed with the other parameters.
CONCLUSIONS: Anti-CCP antibody is prevalent in Malaysian RA patients at 80.4% and more sensitive than RF in our cohort of established RA patients. Even though the anti-CCP levels correlated with RF, it did not show correlation with DAS.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.